Ubs Group Ag Tyra Biosciences, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 10,964 shares of TYRA stock, worth $138,913. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,964

Previous 7,575 44.74%

Holding current value

$138,913

Previous $121,000 112.4%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$16.7 - $24.36 $56,596 - $82,556	3,389 Added 44.74%	10,964 $257,000
Q2 2024 Aug 13, 2024	SELL	$14.45 - $20.22 $95,326 - $133,391	-6,597 Reduced 46.55%	7,575 $121,000
Q1 2024 May 13, 2024	BUY	$11.61 - $20.0 $106,753 - $183,900	9,195 Added 184.75%	14,172 $232,000
Q4 2023 Feb 09, 2024	SELL	$11.01 - $14.95 $3,666 - $4,978	-333 Reduced 6.27%	4,977 $68,000
Q3 2023 Nov 09, 2023	SELL	$13.15 - $16.08 $35,334 - $43,206	-2,687 Reduced 33.6%	5,310 $73,000
Q2 2023 Aug 11, 2023	BUY	$11.99 - $17.51 $40,502 - $59,148	3,378 Added 73.13%	7,997 $136,000
Q1 2023 May 12, 2023	BUY	$6.85 - $16.22 $7,069 - $16,739	1,032 Added 28.77%	4,619 $74,000
Q4 2022 Feb 08, 2023	BUY	$5.68 - $8.81 $19,857 - $30,799	3,496 Added 3841.76%	3,587 $27,000
Q3 2022 Nov 10, 2022	BUY	$6.61 - $12.42 $601 - $1,130	91 New	91 $1,000
Q2 2022 Aug 10, 2022	SELL	$5.26 - $11.19 $9,152 - $19,470	-1,740 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$10.03 - $14.09 $37,441 - $52,597	-3,733 Reduced 68.21%	1,740 $19,000
Q4 2021 Feb 14, 2022	BUY	$12.23 - $31.35 $66,934 - $171,578	5,473 New	5,473 $77,000

Others Institutions Holding TYRA

# of Institutions

103

Shares Held

47.3M

Call Options Held

353K

Put Options Held

1.1K

View Full List

About Tyra Biosciences, Inc.

Ticker TYRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,973,600
Market Cap $532M
Description
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...

More about TYRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account